Bold claim: A single gene variant may set the pace for how well your muscles grow their blood supply, shaping endurance, recovery, and metabolic health. But here’s where it gets controversial... a tiny genetic brake could both boost performance and raise injury risk depending on the context. This is the core idea behind a new rewrite of a Lund University study that maps how our muscles develop their capillary networks and why that matters for athletes and health alike.
What the study found, in plain terms:
- Discovery: A specific gene variant in RAB3GAP2 influences how many capillaries form around muscle fibers, effectively controlling the muscle’s blood supply.
- Why it matters: More capillaries improve oxygen and nutrient delivery to muscles and help remove waste, which enhances endurance, supports metabolism, and shortens recovery time.
- Who it helps most: Endurance athletes show a higher prevalence of the favorable variant compared with sprinters and non-athletes, suggesting a link between this genetic brake and sustained performance.
- Training interaction: High-intensity training can dampen the brake’s effect, promoting more capillary growth and better vascular remodeling.
- Future implications: The finding could enable personalized training plans, targeted rehabilitation, and potential new treatments for metabolic conditions.
How capillaries work (a quick refresher): Capillaries are the smallest blood vessels that feed muscles. More capillaries mean better oxygen and nutrient delivery to muscle cells and faster removal of waste products. For endurance athletes, this is a clear advantage; for sprinters, immediate energy access and muscular power are often more decisive.
In the Swedish portion of the research, scientists analyzed muscle tissue and DNA from just over 600 people and identified a genetic variant linked to capillary density. Endurance athletes, notably cross-country skiers, were about twice as likely to carry this variant—roughly 10% of endurance athletes versus 5% of non-athletes. The variant influences a protein that regulates the growth of new blood vessels around muscle fibers: when the protein’s activity is reduced, more capillaries form.
As the researchers put it, it’s like discovering a genetic brake on new blood vessel formation in muscles. If the brake works less strongly, more capillaries appear, improving oxygen delivery and endurance.
A larger, international study followed, analyzing DNA from top athletes across six countries. The Swedish results held up in European, American, and Asian cohorts, though not in African groups. Interestingly, the variant was extremely rare among elite sprinters—less than 1% of world-class Jamaican sprinters carried it, compared with a small fraction of Jamaican non-athletes.
But the brake isn’t fixed. High-intensity interval training can lower the brake’s impact, effectively releasing the constraint on blood vessel growth. When the braking protein’s activity declines, muscle cells proliferate and capillaries expand, while signals that guide tissue rebuilding ramp up.
This duality helps explain why training boosts both performance and metabolic health, according to Lund researchers. Yet there’s a trade-off: the same variant linked to faster capillary growth is also associated with a heightened inflammatory response and, in some contexts, a greater risk of muscle injuries. In other words, the performance edge comes with potential downsides that must be balanced.
One researcher framed it this way: training is deliberate stress that tunes the body's response. People with this genetic variant start with a higher baseline; training can magnify benefits, but pushing the system too far can impair recovery and raise injury risk.
Beyond basic science, the study emphasizes the practical takeaway: understanding these molecular pathways lays the groundwork for individualized training programs, improved rehabilitation strategies, and new therapies for metabolic diseases.
Looking ahead, the team is collaborating with AstraZeneca to pursue a drug that could help people with muscle insulin resistance by dampening the brake protein and potentially increasing muscle glucose uptake. Such a treatment doesn’t exist today, but this line of research could open new avenues for metabolic health.
Controversial point to consider: if a gene variant predisposes someone to better endurance but higher injury risk, should athletes pursue strategies to optimize its expression or counterbalance its effects through tailored training and recovery protocols? What responsibilities do coaches and medical teams have when genetics suggest both opportunity and risk? Share your thoughts below: Do you think personalized training based on a person’s genetic “brake” should become standard practice, or should we treat such differences with caution to avoid unintended harms?
